Veracyte Revenue and Competitors

Location

$681.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Veracyte's estimated annual revenue is currently $143.7M per year.(i)
  • Veracyte received $58.9M in venture funding in July 2018.
  • Veracyte's estimated revenue per employee is $217,000
  • Veracyte's total funding is $681.3M.

Employee Data

  • Veracyte has 662 Employees.(i)
  • Veracyte grew their employee count by 2% last year.

Veracyte's People

NameTitleEmail/Phone
1
Chief Scientific Officer & Chief Medical OfficerReveal Email/Phone
2
Principal Accounting Officer, VP ControllerReveal Email/Phone
3
CEOReveal Email/Phone
4
Chief Accounting OfficerReveal Email/Phone
5
VP Information SystemsReveal Email/Phone
6
VP Clinical AffairsReveal Email/Phone
7
Head Sales Operations & Commercial AnalyticsReveal Email/Phone
8
VP Marketing & Sales, PulmonologyReveal Email/Phone
9
SVP & General Manager, EndocrinologyReveal Email/Phone
10
VP, Employment Law & Global HRReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$434.8M1865-14%$2B$2.7B
Add Company

What Is Veracyte?

Veracyte is a pioneering genomic diagnostics company. Our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. We ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. We are giving patients a clearer path forward. Through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. Veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. We are making a difference in the lives of physicians and patients. We are doing something real. .

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$681.3M

Total Funding

662

Number of Employees

$143.7M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Veracyte News

2022-04-19 - Veracyte, Inc.'s (NASDAQ:VCYT) recent US$201m market cap decline means a loss of US$24k for insiders who bought this year

Veracyte Insider Transactions Over The Last Year. The Independent Director Jens Holstein made the biggest insider purchase in the last 12 months...

2022-04-17 - Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform...

2022-04-13 - Veracyte, Inc. (NASDAQ:VCYT) Expected to Announce ...

Analysts expect that Veracyte, Inc. (NASDAQ:VCYT – Get Rating) will post earnings per share (EPS) of ($0.23) for the current quarter,...

2021-03-22 - Veracyte Appoints Muna Bhanji to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 22, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately. This press release fe ...

2021-03-15 - Veracyte Completes Acquisition of Decipher Biosciences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 15, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into 7 of the 10 most common cancers ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$116.5M8327%N/A
#2
$748.2M186310%$2.5B
#3
$300M2018-3%$15.6M
#4
$846.5M2458N/AN/A
#5
N/A4008N/AN/A

Veracyte Funding

DateAmountRoundLead InvestorsReference
2010-06-11$28.0MBDomain AssociatesArticle
2013-07-01$28.0MCGE VenturesArticle
2016-03-29$45.0MUndisclosedVisium Healthcare PartnersArticle
2016-11-03$30.0MUndisclosedLeerink Partners LLCArticle
2018-07-27$58.9MUndisclosedLeerink PartnersArticle